Comprehensive market intelligence and assay solutions for RNF128 (GRAIL/GTRAP3-18) targeted immunotherapy development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RNF128 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild Type) | RNF128 Full-Length & RING Domain Protein High purity (>95%), Sequence Verified, Theoretical MW confirmed. E2-binding competent format. Human/Mouse/Cyno orthologs available. |
View RNF128 Products |
| Antigen (Mutant) | RNF128 C212/215S (Catalytically Dead) RING domain mutant for dominant negative studies and assay specificity controls. |
View RNF128 Products |
| Gene Delivery | RNF128 Lentivirus Particles (WT & Mutant) Full-length ORF with CMV promoter for stable T-cell or DC lines. Endotoxin controlled. |
View RNF128 Products |
| Gene Suppression | RNF128 siRNA Set & shRNA Lentivirus For knockdown validation in anergy/exhaustion models. |
View RNF128 Products |
| Substrate Protein | PD-L1 (CD274) Cytoplasmic Domain Protein Validated substrate for ubiquitination assays. High purity (>90%). |
View PD-L1 Products |
| Related Target (Paralog) | CBL-B (CBLB) E3 Ligase Functional homolog in T-cell regulation. Critical for selectivity screening. |
View CBLB Products |
| Related Target (Pathway) | SLC1A1 (EAAC1) Glutamate Transporter Original substrate identifying RNF128 function. Neuronal/glial context. |
View SLC1A1 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| E3 Ligase Activity Detection (Auto-ubiquitination) | RING Domain Protein (>95% purity) with intact Zn-coordination sites. Sequence verified for Cys/His integrity. |
| Substrate Recruitment Specificity | PD-L1 Cytoplasmic Tail available. Confirmed theoretical ubiquitination site mapping (Lys residues). |
| CBL-B vs RNF128 Selectivity | Homolog Panel: Both RNF128 and CBL-B RING domains available for counter-screening. Sequence divergence verified. |
| Cellular Mechanism Validation | Catalytically Dead Mutant (C212/215S) Lentivirus included as negative control for rescue experiments. |
| T Cell Line Engineering | High-titer Lentivirus (>10^8 TU/mL) for stable expression in Jurkat and primary T cells. |
Live RNF128 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for next-generation immune checkpoint inhibitors is expanding beyond PD-1/CTLA-4 to intracellular negative regulators. RNF128 (also known as GRAIL) has emerged as a critical E3 ubiquitin ligase that induces T-cell anergy by ubiquitinating key signaling molecules including PLCγ1 and LAT. Recent findings highlighting its role in PD-L1 stability regulation have positioned RNF128 as a high-value target for solid tumor immunotherapy.
As first-generation PD-1/L1 inhibitors reach market saturation, the next wave is targeting membrane-associated ubiquitin ligases like RNF128 to reprogram T cell fate decisions in both oncology and autoimmune indications. Current development is predominantly preclinical, with lead optimization focused on RING domain inhibitors and PROTAC-mediated degradation strategies. As first-generation small molecules enter IND-enabling studies, the field is pivoting toward combination therapies with existing PD-1 inhibitors to overcome resistance in cold tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Emerging Biotech | Solid Tumors (Melanoma, Lung) | RING Domain Auto-ubiquitination Assay (Need high-purity Zn-binding protein) |
| PROTACs (Targeted Degradation) | Specialized TPD Companies | Autoimmune Diseases | Ternary Complex Formation (Need RNF128 + Ligand + E2 co-complex) |
| Genetic Knockdown | Cell Therapy Developers | CAR-T Enhancement | Stable Cell Line Construction (Lentivirus for T-cell transduction) |
| Peptide Blockers | Innovator Biotech | Inflammatory Disorders | Substrate Competition Assay (PD-L1 ubiquitination inhibition) |